endpts.com·May 14, 2026
Degron Therapeutics, a US-China biotech company, has secured an additional $40 million in a Series A extension, bringing its total funding to $95 million for its molecular glue degrader platform.
Degron Therapeutics' recent $40 million Series A extension highlights strong investor confidence in their molecular glue degrader platform, a promising area in targeted protein degradation. For professionals tracking biotech investments, this signals a growing interest and potential opportunity in platforms that advance precision medicine through novel mechanisms like molecular glue degraders.